Payment overview · 2025
General Payments
$660.66
28 reported records · 9 companies
Healthcare provider profile · identity verified
John Ehum, MD
Allopathic & Osteopathic Physicians|Family Medicine · SANTA ANA, CA · NPI 1942483409
Verified facts
What the public records show
CMS Open Payments records show John Ehum, MD received $660.66 in general payments during 2025 across 28 reported records.
Aimmune Therapeutics, Inc. accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Kerendia, Linzess, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 410 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Prolia by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $205.48 | 31.1% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $94.80 | 14.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $87.32 | 13.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.82 | 12.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.78 | 8.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.00 | 7.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.55 | 5.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.60 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.31 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $660.66 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $205.48 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $87.32 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $82.82 | 4 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $71.15 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $65.47 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $58.78 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 410 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 129 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
410 | 78 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
129 | 23 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
90 | 20 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
74 | 40 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1747 | 405 |
| Amlodipine Besylate | Amlodipine Besylate | 934 | 199 |
| Losartan Potassium | Losartan Potassium | 869 | 188 |
| Metformin Hcl | Metformin Hcl | 690 | 155 |
| Omeprazole | Omeprazole | 631 | 172 |
| Vascepa | Icosapent Ethyl | 544 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 470 | 89 |
| Creon | Lipase/Protease/Amylase | 410 | 78 |
| Lidocaine | Lidocaine | 369 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 356 | 80 |
| Donepezil Hcl | Donepezil Hcl | 335 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 304 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 294 | 52 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 271 | 97 |
| Azithromycin | Azithromycin | 264 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 51 |
| Celecoxib | Celecoxib | 239 | 94 |
| Gabapentin | Gabapentin | 222 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 212 | 37 |
| Januvia | Sitagliptin Phosphate | 198 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 44 |
| Finasteride | Finasteride | 171 | 39 |
| Atenolol | Atenolol | 168 | 40 |
| Alendronate Sodium | Alendronate Sodium | 162 | 46 |
| Glipizide Er | Glipizide | 162 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 59 |
| Lisinopril | Lisinopril | 150 | 35 |
| Furosemide | Furosemide | 148 | 35 |
| Montelukast Sodium | Montelukast Sodium | 141 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 33 |
| Ketoconazole | Ketoconazole | 135 | 36 |
| Tradjenta | Linagliptin | 134 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 133 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 132 | 37 |
| Prednisone | Prednisone | 132 | 101 |
| Metformin Hcl Er | Metformin Hcl | 130 | 28 |
| Linzess | Linaclotide | 129 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 28 |
| Baclofen | Baclofen | 127 | 67 |
| Trazodone Hcl | Trazodone Hcl | 125 | 30 |
| Simvastatin | Simvastatin | 123 | 26 |
| Clonidine Hcl | Clonidine Hcl | 111 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 102 | 24 |
| Amoxicillin | Amoxicillin | 100 | 73 |
| Doxazosin Mesylate | Doxazosin Mesylate | 100 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 94 | 18 |
| Jardiance | Empagliflozin | 93 | 20 |
| Lovastatin | Lovastatin | 92 | 18 |
| Zenpep | Lipase/Protease/Amylase | 90 | 20 |
| Memantine Hcl | Memantine Hcl | 79 | 15 |
| Glimepiride | Glimepiride | 78 | 15 |
| Carvedilol | Carvedilol | 76 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 15 |
| Prolia | Denosumab | 74 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 22 |
| Hydrocortisone | Hydrocortisone | 66 | 27 |
| Farxiga | Dapagliflozin Propanediol | 64 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 63 | 14 |
| Clotrimazole | Clotrimazole | 61 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 59 | 14 |
| Ozempic | Semaglutide | 58 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 12 |
| Ciclopirox | Ciclopirox | 56 | 11 |
| Eliquis | Apixaban | 56 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 55 | 12 |
| Meclizine Hcl | Meclizine Hcl | 54 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 12 |
| Meloxicam | Meloxicam | 53 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 13 |
| Ezetimibe | Ezetimibe | 51 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 15 |
| Potassium Chloride | Potassium Chloride | 49 | 12 |
| Memantine Hcl Er | Memantine Hcl | 47 | suppressed |
| Restasis | Cyclosporine | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | suppressed |
| Glipizide | Glipizide | 44 | suppressed |
| Praluent Pen | Alirocumab | 44 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 43 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | suppressed |
| Tadalafil | Tadalafil | 41 | suppressed |
| Valsartan | Valsartan | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 38 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 37 | 12 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 23 |
| Tramadol Hcl | Tramadol Hcl | 33 | 17 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Ztlido | Lidocaine | 32 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Kerendia | Finerenone | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Dexamethasone | Dexamethasone | 26 | 21 |
| Famotidine | Famotidine | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 11 |
| Dexilant | Dexlansoprazole | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Procto-Med Hc | Hydrocortisone | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Flector | Diclofenac Epolamine | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | 12 |
| Telmisartan | Telmisartan | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Brilinta | Ticagrelor | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Propylthiouracil | Propylthiouracil | 14 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Miglitol | Miglitol | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $660.66 · 28 records | Aimmune Therapeutics, Inc. | CREON, EVENITY, FREESTYLE LIBRE 3, ID NOW INSTRUMENT, JARDIANCE, Kerendia, LINZESS, MOUNJARO, Ozempic, REXULTI, Repatha, ZENPEP | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error